ProQR Therapeutics (PRQR) Cash & Equivalents (2012 - 2026)

ProQR Therapeutics has reported Cash & Equivalents for 15 years, with the latest figure at $94.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 31.83% year-over-year to $94.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.9 million (down 31.83% YoY) and the FY2025 annual result came in at $107.6 million, down 32.62% from the prior year.
• Cash & Equivalents declined to $94.9 million in Q1 2026 per PRQR's latest filing, from $107.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $188.1 million in Q1 2022 and troughed at $85.0 million in Q2 2024.
• A 5-year average of $125.9 million and a median of $128.0 million in 2023 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 129.76% in 2022, down 54.93% in 2022.
• Over 5 years, Cash & Equivalents stood at $96.7 million in 2022, then jumped by 32.33% to $128.0 million in 2023, then gained by 24.77% to $159.7 million in 2024, then slumped by 32.62% to $107.6 million in 2025, then fell by 11.74% to $94.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $94.9 million, $107.6 million, and $125.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.